State-of-the-art lecture on GPVI targeting at the GTH Congress 2026 in Bonn, Germany. Emfret´s lead candidate EMA601 underscores its high potential as first-in-class GPVI inhibitor.
Eibelstadt/Würzburg/Bonn – 18 February 2026
At the GTH (German Society of Thrombosis and Haemostasis) Congress 2026 in Bonn, a State-of-the-Art lecture on “Targeting platelet GPVI in thrombosis and thrombo-inflammation” highlighted the growing therapeutic relevance of GPVI inhibition. The presentation, given by Prof. Bernhard Nieswandt from Julius-Maximilians-Universität Würzburg (JMU), summarized current insights into GPVI function, its regulation in platelets, and its central role in thrombo-inflammatory disease processes.
The lecture provided an overview of existing GPVI-targeting strategies and ongoing clinical developments, emphasizing that effective therapeutic intervention requires robust and sustained inhibition of GPVI signaling.
In this context, EMFRET Analytics’ humanized anti-platelet glycoprotein VI Fab fragment EMA601 was presented as a next-generation inhibitor, demonstrating more than 50-fold higher potency compared to existing GPVI-targeting approaches in preclinical studies.
The data position EMA601 as a promising candidate for future clinical development, with potential applications in stroke and other thrombo-inflammatory diseases where selective inhibition of platelet activation is required.
